Genomic Signature May Identify Breast Cancer Patients Who Can Safely Forgo Adjuvant Radiotherapy
The signature was prognostic for locoregional recurrence.
Breast Cancer
Chemotherapy Doesn’t Increase the Risk of COVID-19 or Related Death in Patients with Breast Cancer, Study Suggests
Rates of SARS-CoV-2 infection and COVID-19-related death were similar among patients receiving cytotoxic and non-cytotoxic therapy.
Endocrine Therapy Proves Noninferior to Chemotherapy in HR+, HER2+ Metastatic Breast Cancer
Endocrine therapy was associated with fewer adverse events.
Underdosing in Patients With Cancer and Obesity: A Thing of the Past?
New guidelines recommend using the full approved doses of immunotherapy and targeted therapies for patients with cancer and obesity.
Age and Stage at Breast Cancer Diagnosis Don’t Account for Racial Disparities in Distant Metastases
Black patients were more likely than White patients to have distant metastases.
Abemaciclib Plus Endocrine Therapy Deemed Beneficial in High-Risk Early Breast Cancer After Neoadjuvant Chemo
The combination improved invasive disease-free survival and distant relapse-free survival.
Dual HER2 Blockade With Taxane Improves Pathologic Complete Response and Survival in Breast Cancer
Early pCR after only 12 weeks of neoadjuvant paclitaxel plus pertuzumab and trastuzumab was strongly associated with improved outcomes.
70-Gene MammaPrint Assay Predicts Survival Benefit With Letrozole in Low-Risk Breast Cancer
Statistically significant benefit was observed with extended letrozole therapy in patients with HR+ breast cancer identified as low-risk, but not in high-risk patients.
MammaPrint 70-Gene Signature Identifies Ultralow-Risk Patients With Outstanding Prognosis in Breast Cancer
The 70-gene signature can identify patients with an ultralow risk of distant recurrence, which can be used to de-escalate treatment and reduce side effects.
Olaparib Improves Survival in High-Risk, BRCA-Mutated, HER2-Negative Early Breast Cancer
Adjuvant olaparib treatment resulted in fewer deaths in patients with germline BRCA1/2 mutations and high-risk HER2-negative primary breast cancer.
- Loading...
Loading...
Next post in ASCO 2021
Loading... 
Loading...